

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	23 June 2017
Date of last disclosure:	27 March 2017
Director or senior manager giving disclosure	
Full name(s): Name of listed issuer:	Claire Higgins
Name of related body corporate (if applicable):	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	Director of Vital Healthcare
Position held in listed issuer:	Management Limited
t Commence of acquirities are disposed of relavant interest (available a qualified stationt).	
Summary of acquisition or disposal of relevant interest (excluding specified derivative	
Class of affected quoted financial products:	Ordinary units
Nature of the affected relevant interest(s):	Legal and beneficial owner of units
For that relevant interest-	
Number held in class before acquisition or disposal:	75,950
Number held in class after acquisition or disposal:	76,679
Current registered holder(s):	Adam L Higgins Superannuation Fund
Registered holder(s) once transfers are registered:	
Summary of acquisition or disposal of specified derivatives relevant interest (if applie	cable)
Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	[
Date of transaction:	22 June 2017
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration;	\$ 1,613.94
Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	729
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	INU
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	All Barris
Date of signature:	23 June 2017
Name and title of authorised person:	Stuart Harrison - Company Secretary

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	23 June 2017
Date of last disclosure:	27 March 2017
Director or senior manager giving disclosure	
Full name(s):	Graeme Horsley
Name of listed issuer:	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director of Vital Healthcare
	Management Limited
l Summary of acquisition or disposal of relevant interest (excluding specified derivativ	res)
Class of affected quoted financial products:	Ordingnumita
Nature of the affected relevant interest(s):	Ordinary units Beneficial owner (the units are held by the registered holder for the Graeme Horsley No 3 Trust of which Graeme
	Horsley is a trustee and beneficiary)
For that relevant interest-	
Number held in class before acquisition or disposal:	293,078
Number held in class after acquisition or disposal:	295,891
Current registered holder(s):	Graeme Horsley No 3 Trust
Registered holder(s) once transfers are registered:	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied	cable)
Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	22 June 2017
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$ 6,227.91
Number of financial products to which the transaction related:	2,813
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal: Class of quoted financial products: N/A N/A Nature of relevant interest: For that relevant interest,-Number held in class: Current registered holder(s): For a derivative relevant interest,-Type of derivative: Details of derivative,-The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest,-Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: Date of signature: Signature of person authorised to sign on behalf of director or officer: 23 June 2017 Date of signature: Stuart Harrison - Company Secretary Name and title of authorised person:

Notes

Use this form to disclose all the acquisitions—and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

	1
To NZX Limited; and	
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	23 June 2017
Date of last disclosure:	27 March 2017
Director or senior manager giving disclosure	
Full name(s):	Andrew Evans
Name of listed issuer:	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	Vital Fleatificate Floperty Frost
	Director of Vital Healthcare
Position held in listed issuer:	Management Limited
Summary of acquisition or disposal of relevant interest (excluding specified derivat	ives)
Class of affected quoted financial products:	Ordinary units
	Legal and beneficial owner of certain
Nature of the affected relevant interest(s):	units, and Non-Beneficial owner (units held by the registered holder for the Graeme Horsley No 3 Trust of which Andrew Evans is a trustee) of certain units
For that relevant interest-	01110
Number held in class before acquisition or disposal:	725,455
Number held in class after acquisition or disposal:	732,419
Current registered holder(s):	The Bassett Trust and Graeme Horsley
Registered holder(s) once transfers are registered:	No 3 Trust
- vagination (e) and a distribution and registration	
Summary of acquisition or disposal of specified derivatives relevant interest (if app	licable)
Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	22 June 2017
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into	
a cash value, describe the consideration:	\$ 15,415.92
Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	6,964
Whether relevant interests were acquired or disposed of during a closed period:	No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
Or	
Signature of person authorised to sign on behalf of director or officer:	Moleon
Date of signature:	23 June 2017
Name and title of authorised person:	Stuart Harrison - Company Secretary

Notes

Use this form to disclose all the acquisitions—and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.